查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球数位剂量吸入器市场 -2023-2030
市场调查报告书
商品编码
1374806

全球数位剂量吸入器市场 -2023-2030

Global Digital Dose Inhalers Market -2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 186 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

数位剂量吸入器是一种呼吸辅助设备，可以与电子设备连接以每天检查患者的健康状况。这些对于患有气喘或阻塞性疾病等呼吸道疾病的人特别有帮助。这些吸入器中的感测器会提示使用者每天在适当的时间服药。

数位剂量吸入器健康系统使用机电感测器和微电子技术来监测吸入器的驱动。一些小工具包括连结的智慧型手机、与患者通讯的行动应用程式、云端伺服器以及供医生查看仪表板资料的入口网站。

一些数位剂量吸入器可以测量污染或花粉水平，或在患者忘记时发出警报。智慧吸入器会通知患者漏服或重复服药，并提醒他们按时、自动、轻鬆地服药。

市场动态：驱动因素与限制因素

呼吸道疾病盛行率上升

呼吸道疾病盛行率的上升是预测期内帮助市场成长的关键驱动因素之一。由于哮喘和慢性阻塞性肺病等呼吸系统疾病的增加，数位剂量吸入器设备的使用经常被迅速使用，这确实会促进市场成长。

例如，根据疾病管制与预防中心的数据，慢性阻塞性肺病估计影响 2 亿人，每年有 320 万人死亡，使其成为全球第三大死因。

气喘是最常见的非传染性疾病之一，影响全球 2.62 亿人。预计到 2022 年，肺癌新病例将接近 220 万，死亡人数将达 180 万，肺癌占全球癌症死亡人数的四分之一。下呼吸道感染或肺炎是重要的死亡原因，每年造成超过 240 万人死亡，主要发生在低收入和中等收入国家 (LMIC)。 COVID-19 显着增加了全球肺炎死亡人数。

此外，吸入器技术进步、数据驱动的医疗保健、老年人口盛行率的上升以及远距医疗等的成长将在预测期内进一步推动市场。

市场动态：克制

许多限制因素阻碍了预测期内的市场成长，其中包括药物成本增加和与设备相关的高成本、隐私和资料安全问题、监管障碍以及人们对气喘的先进治疗和设备缺乏认识将阻碍市场成长。

目录

第 1 章：方法与范围

  • 研究方法论
  • 报告的研究目的和范围

第 2 章：定义与概述

第 3 章：执行摘要

  • 按设备类型分類的片段
  • 按应用程式片段
  • 按类型分類的片段
  • 按配销通路分類的片段
  • 按地区分類的片段

第 4 章：动力学

  • 影响因素
    • 司机
      • 呼吸道疾病盛行率上升
      • 科技进步的崛起
    • 限制
      • 安全问题
    • 机会
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • 俄乌战争影响分析
  • DMI 意见

第 6 章：COVID-19 分析

  • COVID-19 分析
    • 新冠疫情爆发前的情景
    • 新冠疫情期间的情景
    • 新冠疫情后的情景
  • COVID-19 期间的定价动态
  • 供需谱
  • 疫情期间政府与市场相关的倡议
  • 製造商策略倡议
  • 结论

第 7 章：按装置类型

  • 定量吸入器
  • 干粉吸入器

第 8 章：按应用

  • 气喘
  • 慢性阻塞性肺病
  • 其他的

第 9 章：按类型

  • 品牌化
  • 通用的

第 10 章：按配销通路

  • 医院药房
  • 零售药局
  • 网路药局

第 11 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 亚太其他地区
  • 中东和非洲

第 12 章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 13 章：公司简介

  • Novartis International AG
    • 公司简介
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • Propeller Health
  • H&T Presspart Manufacturing Ltd
  • AptarGroup Inc
  • Amiko Digital Health Limited
  • Trudell Medical UK Limited
  • ReciPharm
  • Sensirion
  • Teva Pharmaceuticals
  • Cohero Health, Inc

第 14 章：附录

简介目录
Product Code: MD7244

Overview

Digital dose inhalers are breathing aids that can be linked to electronic devices to check on a patient's health every day. These are especially helpful for people with respiratory diseases like asthma or obstructive diseases. Sensors in these inhalers prompt the user to take medicine at the appropriate times each day.

Digital dose inhaler health systems use electromechanical sensors and microelectronics to monitor inhaler actuation. Some gadgets include a linked smartphone, a mobile app that communicates with the patient, a cloud server, and a portal for the physician to see dashboard data.

Some digital dose inhalers can measure pollution or pollen levels or alarm patients if they forget them. Smart inhalers notify patients of missed or repeated doses and remind them to take their dosages on time, automatically, and easily.

Market Dynamics: Drivers and Restraints

Rise in prevalence of respiratory diseases

The rise in the prevalence of respiratory disease is one of the key drivers that helps the market to grow during the forecast period. Since the rise in respiratory diseases like asthma and COPD the use of digital dose inhaler devices is often used rapidly which indeed will increase the market growth.

For instance, according to the Centers for Disease Control and Prevention COPD affects an estimated 200 million people, with 3.2 million dying each year, making it the third-leading cause of mortality globally.

Asthma is one of the most common noncommunicable illnesses, impacting 262 million people worldwide. With almost 2.2 million new instances of lung cancer expected in 2022 and 1.80 million fatalities, lung cancer accounts for one in every four cancer deaths worldwide. Lower respiratory tract infection or pneumonia is a prominent cause of death, accounting for more than 2.4 million fatalities each year, primarily in low and middle-income countries (LMICs). COVID-19 has significantly increased pneumonia fatalities worldwide.

Furthermore, technological advancements in technological advancements in inhalers, Data-Driven Healthcare, the rise in the prevalence of the geriatric population, and rise in the telemedicine's and others will further drive the market during the forecast period.

Market Dynamics: Restraint

Many restraint factors hampers the market growth during the forecast period some of the mare like, increasing medication cost and high cost associated with devices, privacy and data security concerns, regulatory hurdles, and lack of awareness among people regarding advanced treatment and devices available for asthma are going to impede the market growth.

Segment Analysis

The global digital dose inhalers is segmented based on product type, type, application, type, distribution channel and region.

The metered-dose inhaler from the device type segment accounted for approximately 41.2% of the market share

The metered-dose inhaler from the device type segment accounted for 41.2% and it is expected to be dominated during the forecast period. A metered-dose inhaler has a pressurized canister of medication that fits into a mouthpiece. In most instances, a dose of medication is released into your lungs by pushing the canister into the mouthpiece. Another type releases medication automatically when you inhale. Some metered-dose inhalers have counters that track how many doses remain.

For instance, on July 2023, Hormosan Pharma GmbH (Hormosan), Lupin's wholly-owned subsidiary in Germany, stated that they have been launched Luforbec 100/6 (beclometasone 100µg / for motel 6µg), a fix combination in a pressurized metered dose inhaler (pMDI) for the treatment of adult asthma and chronic obstructive pulmonary disease (COPD) in Germany.

Moreover, on February 8 2022, Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, stated the launch of HeroTracker Sense, a novel digital respiratory health solution that transforms a standard metered dose inhaler (pMDI) into a smart connected healthcare device.

HeroTracker Sense is designed to help improve the lives of patients around the world suffering from chronic respiratory diseases such as asthma, COPD, Cystic Fibrosis and other respiratory conditions caused by COVID-19, to track their usage and facilitate improved adherence to their prescribed therapy.

Geographical Analysis

North America accounted for approximately 38.4% of the market share in 2022

North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to rigorous research and development activities and increased awareness regarding the currently available hi-tech respiratory devices. In addition, an upsurge in the prevalence of respiratory conditions among both the pediatric and elderly populations will boost the market growth over the forecast years.

For instance, in September 2020, Teva Pharmaceuticals launched the AirDuo Digihare and ArmonAir Digihaler inhalation powder, two digital maintenance inhalers for patients with asthma.

COVID-19 Impact Analysis

COVID-19 had a substantial impact on the global digital dose inhalers market importantly on asthma for instance, according to the article titled "Risk of serious COVID-19 outcomes among adults with asthma in Scotland: a National Incident Cohort Study" published in January 2022 adults with asthma were found to be at an increased risk of COVID-19 hospital admission compared with those without asthma conditions. Thus, increasing cases of COVID-19 are raising the cases of respiratory disorders which generates the need for digital dose inhalers.

Competitive Landscape

The major global players in the digital dose inhalers market include: Novartis International AG, Propeller Health, H&T Presspart Manufacturing Ltd, AptarGroup Inc, Amiko Digital Health Limited, Trudell Medical UK Limited, ReciPharm, Sensirion, Teva Pharmaceuticals, Cohero Health, Inc and among others.

Key Developments

  • In February 2022, AstraZeneca and Honeywell partnered to develop next-generation respiratory inhalers using the propellant HFO-1234ze, which has up to 99.9% less global warming potential than propellants currently used in respiratory medicines.
  • In October 2020, Zydus launched a pressurised Metered Dose Inhaler for COPD patient.

Why Purchase the Report?

  • To visualize the global digital dose inhalers market segmentation-based device type, application, type, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development
  • Excel data sheet with numerous data points of digital dose inhalers market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global digital dose inhalers market report would provide approximately 69 tables, 70 figures, and 185 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Device Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by Type
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Driver
      • 4.1.1.1. Rise in the prevalence of respiratory diseases
      • 4.1.1.2. Rise in the technology advancements
    • 4.1.2. Restraints
      • 4.1.2.1. Security issues
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Device Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 7.1.2. Market Attractiveness Index, By Device Type
  • 7.2. Metered Dose Inhalers *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Dry Powder Inhalers

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Asthma *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. COPD
  • 8.4. Others

9. By Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.1.2. Market Attractiveness Index, By Type
  • 9.2. Branded *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Generic

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospital Pharmacies *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Novartis International AG
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Propeller Health
  • 13.3. H&T Presspart Manufacturing Ltd
  • 13.4. AptarGroup Inc
  • 13.5. Amiko Digital Health Limited
  • 13.6. Trudell Medical UK Limited
  • 13.7. ReciPharm
  • 13.8. Sensirion
  • 13.9. Teva Pharmaceuticals
  • 13.10. Cohero Health, Inc

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us